At Differentiated Therapeutics, founded in 2021, protein proximity is mapped in order to design disease-modifying degrader therapeutics for indications with high unmet clinical needs. Their proprietary AI-driven Auto/dx Platform allows the determination of genetically defined disease drivers that can be targeted with small molecule protein degraders for a wide array of diseases. Co-founders Bryce Allen, Isaac Kohane, and Diala Ezzeddine have expertise in Data Science, Biomedical Research, and Immuno-Oncology drug development.

Differentiated Therapeutics

Founded: 2021
Location: Boston, MA
Employee range: 1 - 10
Clinical stage: RD
Therapy area: Genetic diseases
Drug types: GEN
Lead product: Undisclosed
Funding: $5M seed Aug 2022

About:

Jobs: